Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
Swiss Cancer Institute
M.D. Anderson Cancer Center
CRISPR Therapeutics
Incyte Corporation
Young Adult Survivors United
M.D. Anderson Cancer Center
Scripps Translational Science Institute
Washington University School of Medicine
M.D. Anderson Cancer Center
Thomas Jefferson University
Amgen
Thomas Jefferson University
Thomas Jefferson University
Fred Hutchinson Cancer Center
Zhejiang DTRM Biopharma
Beijing Boren Hospital
Servier
Cyclacel Pharmaceuticals, Inc.
Pfizer
Celgene
Amgen
Therapeutic Advances in Childhood Leukemia Consortium
Fate Therapeutics
Bellicum Pharmaceuticals
Eastern Cooperative Oncology Group
Albert Einstein College of Medicine
Jewish General Hospital
Bristol-Myers Squibb
OHSU Knight Cancer Institute
Molecular Templates, Inc.
South Plains Oncology Consortium
Sanofi
Brown University
Spectrum Pharmaceuticals, Inc
Takeda
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, San Diego
Gilead Sciences
Masonic Cancer Center, University of Minnesota
Alliance for Clinical Trials in Oncology
University of Texas Southwestern Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mirror Biologics, Inc.
Gilead Sciences